Changes to the rare disease test directory were published on 8th April. Key changes include developmental disorders, chromosomal analysis, inherited cancer and neurological conditions.
Changes to the cancer test directory were published on 8th April. This includes the first moves towards a digital test directory and additional DPYD pharmacogenomic targets.